Predictive and Clinical Immunogenicity, Merck & Co., Inc., Kenilworth, New Jersey, USA.
AAPS J. 2021 Jan 18;23(2):26. doi: 10.1208/s12248-020-00553-x.
Accurate assessment of antigen-specific immune responses is critical in the development of safe and efficacious biotherapeutics and vaccines. Endosomal processing of a protein antigen followed by presentation on major histocompatibility complex (MHC) class II constitute necessary steps in the induction of CD4+ T cell immune responses. Current preclinical methods for assessing immunogenicity risk consist of in vitro cell-based assays and computational prediction tools. Cell-based assays are time and labor-intensive while in silico methodologies have limitations. Here, we propose a novel cell-based assay capable of investigating an antigen's endosomal processing and MHC class II presentation capabilities. This novel assay relies on competition between epitopes for MHC class II binding and employs labeled soluble T cell receptors (sTCRs) as detectors of epitope presentation.
准确评估抗原特异性免疫应答对于开发安全有效的生物治疗药物和疫苗至关重要。蛋白抗原的内体处理,随后主要组织相容性复合物(MHC)II 类呈递,是诱导 CD4+T 细胞免疫应答的必要步骤。目前评估免疫原性风险的临床前方法包括体外基于细胞的测定和计算预测工具。细胞测定既耗时又费力,而计算方法存在局限性。在这里,我们提出了一种新的基于细胞的测定方法,能够研究抗原的内体处理和 MHC Ⅱ类呈递能力。这种新的测定方法依赖于表位与 MHC Ⅱ类结合的竞争,并利用标记的可溶性 T 细胞受体(sTCR)作为表位呈递的检测物。